Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-dependent Effects on Signaling Onset and Duration.
David J. Unett, Joel Gatlin, Todd L. Anthony, Daniel J. Buzard, Steve Chang, Chuan Chen, Xiaohua Chen, Huong T.-M. Dang, John Frazer, Minh K. Le, Abu J. M. Sadeque, Charles Xing & Ibragim Gaidarov.
Departments of Receptor Pharmacology (DJU, JG, TLA, SC, XC, HTMD, JF, MKL, CX & IG), Chemistry (DJB), Drug Metabolism & Pharmacokinetics (CC, AJMS)
in the patent wrld who ever files first wins.... we have file now 19 patents... several have to do with compounds 5-HT2B Agonist ... those are direct pateent... we also have files at least two patents on perparing the receptor and this controling the Effects on Signaling Onset and Duration.,,, My strong belief is ACAD infringes on the perparing the recpetor.. their drug use the same componet that we call out in our patent.... our patent calls out this is a patent it is for preparing the receptor..... my guess is.. so ACAD seems to infringe which would me royalty payments 5 to 7% is
Temanogrel =5-HT2A inverse agonists ............ ARNA
Pimavanserin'=5-HT2A inverse agonists.............ACAD
two type of patents... Method.... specifc.....
ANRA has two method patents... preparing recptor & Effects on Signaling Onset and Duration.
read my earlier post Long ARNA.... no postion in ACAD!!!!! ( not short)
do google search... read before discounting...